A molecular diagnostics company wants to expand its new cartridge-based platform to help orthopedic surgeons make more informed care decisions for patients with a potential joint infection.
Here’s what was new in the world of medical device suppliers during the week of January 14.
Obalon Therapeutics, developer of the first FDA-approved swallowable, gas-filled balloon for obesity treatment, is preparing an underwritten public offering of its common stock.
The IRS and the U.S. Treasury Department have decided to give medical device companies relief from failure to deposit penalties for the first three quarters of 2018.
Toxicologists offer their perspectives on the future of testing.
Trevor Fish, M.S., serves as associate toxicologist, and Sarah C. Campbell, PhD, DABT, serves as senior toxicologist, for Nelson Laboratories LLC (Salt Lake City, UT).
Scientists in Australia have developed an ingestible sensor to detect and measure gut gasses in the stomach. The data can be sent to a phone or computer and could change the way gut disorders are diagnosed and treated.
FDA and Zoll Medical are warning LifeVest 4000 patients to have the device replaced immediately if a specific error message appears on the screen of the wearable defibrillator.
The company recently prevailed in two separate legal battles; one involved a whistleblower lawsuit, and the other was over attorney fees from an old patent case.
General Electric is considering breakup options after taking a major tax hit related to an old portfolio of long-term care insurance.